Biotech Values

[mcbio]

CUV.AX / CLVLY / CLVLF -

Well not that Clinuvel goes against your general statement because their history is quite bad! They do seem to have things turned around (though still bad management smile) and have about doubled in the past year as they are starting EU rollout and (IMO perhaps more significant) they seem to have a path forward with FDA with their messy data package which could lead to filing perhaps later this year and 2017 launch. Their drug is Scenesse for a very rare disease EPP and they hope to develop it/other compounds in larger skin conditions. I think just on EPP it was/is a good investment.

Disclosure: I'm long and also have it in my SI charity portfolio (my best pick)

Congrats on this one as they seem to be doing better than your typical small-cap Australian biotech. I heard of them before and thought they seemed kind of interesting. I assume EPP is quite an unmet need so you would think there would be a bit lower bar for approval. Not sure what their specific issues have been (if more on efficacy front or safety or other).